

References

- Abassi A. and Mansourian A.R. (2007):*** Efficacy of DOTS strategy in treatment of respiratory tuberculosis in Gorgan, Islamic Republic of Iran. Eastern Mediterranean Health Journal; Volume. 13; 3: 112.
- Abaza R.B. (1982):*** Follow up study of tuberculosis in Khalifa region in the years 1975-1980. Thesis for Master degree (chest), Al-Azhar University, p. 72, 73.
- Abd El-hamid A. A. (1981):*** Review of the results of radiology and sputum examination in Sohag dispensary in the years 1976-1980, Thesis for Master degree (chest), Ain-Shams University.
- Abd-Elghany S. (1983):*** Tuberculin surveys and their value in studying some epidemiological aspects of tuberculosis in Assiut University. Master Degree. Assiut University.
- Adapted from Treatment of tuberculosis. (2003):*** guidelines for national programmes, 3rd ed. geneva, World Health Organization, 2003 (WHO/cdS/TB/2003.313).
- Ahlburg D. (2000):*** The economic impacts of tuberculosis. Geneva, World Health Organization, 2000 (document WHO/CDS/STB/2000.5; Stop TB Initiative series).
- Al-Aarag H. A. (1983):*** morbidity and mortality from pulmonary Tuberculosis in Benha region. Master degree, Benha Faculty of Medicine, Zagazig University, 1983.
- Allen BW, Mitchison DA, Chan YC, Yew WW, Allan WG, and Girling DJ. (1983):*** Amikacin in the treatment of pulmonary tuberculosis. Tubercle 1983;64:111-118.
- American Academy of Pediatrics. Tuberculosis. (2000):*** In: Pickering LK, editor. Red book report of the Committee on

Infectious Diseases, 25th edition. Elk Grove Village, IL: American Academy of Pediatrics, 2000: 593--613.

American Thoracic Society. (1994): Centers for Disease Control and Prevention. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359--1374.

American Thoracic Society. (1999): Centers for Disease Control and Prevention. and Infectious Diseases Society of America Treatment of tuberculosis and tuberculosis infection in adults and children. 1999.

American thoracic society. (1999): Diagnostic Standards and Classification of Tuberculosis in Adults and Children 1999.

American Thoracic Society. (2003): CDC, and Infectious Diseases Society of America - June 20, 2003 / 52(RR11);1-77 - Treatment of Tuberculosis.

American Thoracic Society; Centers for Diseases control and prevention.. (2005): Infectious Diseases of American Thoracic Society. Centers for Disease control and prevention/ Infectious Diseases Society of America: Controlling tuberculosis in the United States. Am. J. Respir. Crit. Care. Med.172:1169-1227.

An expanded DOTS framework for effective tuberculosis control. (2002): Geneva, World Health Organization, 2002 (WHO/CDS/TB/2002.297).

Anderson DG, and Jewell M. (1945): The absorption, excretion, and toxicity of streptomycin in man. N Engl J Med 1945;210:421--430.

Anti-tuberculosis drug resistance in the world. (2004): report no. 3, prevalence and trends. WHO/HTM/TB/2004. 343. Geneva (Switzerland)7 World Health Organization.

- Appel GB, and Neu HC. (1977):** The nephrotoxicity of antimicrobial agents [second of three parts]. *N Engl J Med* 1977;296:722-728.
- Aquinas M, and Citron KM. (1972):** Rifampicin, ethambutol, and capreomycin in pulmonary tuberculosis, previously treated with both first and second line drugs: the results of 2 years' chemotherapy. *Tubercle* 1972;53:153--165.
- Arango, L., A. W. Brewin, and J. F. Murray. (1978):** The spectrum of tuberculosis as currently seen in a metropolitan hospital. *Am. Rev. Respir. Dis.* 108:805-S12.
- Baciewicz AM, and Self TH. (1985):** Isoniazid interactions. *South Med J* 1985;78:714-718.
- Badri M, Wilson D, and Wood R. (2002):** Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. *Lancet* 2002;359(9323): 2059– 64.
- Ball P, and Tillotson G. (1995):** Tolerability of fluorquinolone antibiotics: past, present, and future. *Drug Saf* 1995;13:343--358.
- Baruwa P, Prasad R, Jagannath K, and Thakker R.M. (2005):** Efficacy of a four-fixed dose combination in sputum positive Indian patients with pulmonary tuberculosis. *Indian medical Gazette* April 2005.
- Black M, Mitchell JR, Zimmerman HJ, Ishak KG, and Epler GR. (1975):** Isoniazid associated hepatitis in 114 patients. *Gastroenterology* 1975;69:289--302.
- Black RE, Lau WK, Weinstein RJ, Young LS, Hewitt WL. (1976):** Ototoxicity of amikacin. *Antimicrob Agents Chemother* 1976;9:956-961.
- Bonnet m et al. (2007):** reducing the number of sputa examined, and thresholds for positivity: an opportunity to optimize smear

microscopy. International Journal of Tuberculosis and Lung Disease, 2007.

Borgdorff MW, Nagelkerke NJ, Dye C, and Nunn P. (2000): Gender and tuberculosis a comparison of prevalence surveys with notification data to explore sex differences in case detection. Int J Tuberc Lung Dis. 2000 Dec; 4(12):1191-2.

Brasil MT, Opromalla DV, Marzliak ML, and Noguelra W. (1996): Results of a surveillance system for adverse effects in leprosy's WHO/MTD. Int J Lepr Mycobact Dis 1996; 64:97-104.

Burman WJ, and Reves RR. (2000): Review of false-positive cultures for Mycobacterium tuberculosis and recommendations for avoiding unnecessary treatment. Clin Infect Dis 2000; 31: 1390-5.

Caiaffa WT, Graham NMH, Galai N, Rizzo RT, Nelson KE, and Vlahov D. (1995): Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection. Arch Intern Med 1995; 155:2111-2117.

Cameron, S. J. (1974): Tuberculosis and the blood. Tubercle 55:55-72.

Campagna M, Calix AA, and Hauser G. (1954): Observations on the combined use of pyrazinamide (aldinamide) and isoniazid in the treatment of pulmonary tuberculosis. Am Rev Tuberc 1954; 69:334-350

Carr, W. P. J., R. A. Kyle, and E. J. W. Bowie. (1964): Hematologic changes in tuberculosis. Am. J. Med. Sci. 248:707-714.

Caruso AM, Serbina N, Klein E, Triebold K, Bloom BR, and Flynn JL. (1999): Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol 1999; 162: 5407-16.

- Cato A, Cavanaugh J, Shi H, Hsu A, Leonard J, Granneman GR. (1998):** The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998; 63:414-421.
- Cawthorne T, and Ranger D. (1957):** Toxic effect of streptomycin upon balance and hearing. BMJ 1957; 1:1444-1446.
- Central Agency for Public Mobilisation and Statistics report. (1999).**
- Central Agency for Public Mobilisation and Statistics report. (2003).**
- Central Agency for Public Mobilisation and Statistics report. (2008).**
- Chadha S.L. and Bhagi R.P. (2000):** Treatment outcome in tuberculosis patients placed under directly observed treatment short course (DOTS). Ind. J. Tub. 47,155.
- Chauhan A, Madiraju MV, and Fol M. (2006):** Mycobacterium tuberculosis cells growing in macrophages are filamentous and deficient in FtsZ rings. J Bacteriol 2006; 188: 1856-65.
- Collins HL, and Kaufmann SHE. (2002)::** Acquired Immunity against Bacteria. In: Immunology of Infectious Diseases. Chapter 15 Eds: SHE Kaufmann, A Sher & R Ahmed. ASM Press, Washington DC 2002 pp 207-21.
- Comstock, GM. (1999):** How much isoniazid is needed for prevention of tuberculosis in immunocompetent adults. Int J Tuberc Lung Dis 1999; 3:847.
- Conway N, and Birt BD. (1965):** Streptomycin in pregnancy: effect on the foetal ear. BMJ 1965; 2:260-263.
- Corbett EL, Steketee RW, and ter Kuile FO. (2002):** HIV-1/AIDS and the control of other infectious diseases in Africa [published erratum in Lancet 2002; 360(9340):1178]. Lancet 2002;359(9324):2177-87.

- Crofton J, Chaulet P, and Maher D. (1996):** Guidelines for the management of drug-resistant tuberculosis. WHO/TB/96.210. Geneva (Switzerland) 7 World Health Organization; 1996.
- Cullen JH, Early LJ, and Fiore JM. (1956):** The occurrence of hyperuricemia during pyrazinamide--isoniazid therapy. *Am Rev Tuberc* 1956; 74:289-292.
- Curley C. (2003):** New guidelines: what to do about an unexpected positive tuberculin skin test. *Cleve Clin J Med* 2003; 70: 49-55.
- Dannenberg AM Jr. (1991):** Delayed-type hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosis. *Immunol Today* 1991; 12: 228-33.
- Dautzenberg B, Olliaro P, Ruf B, Esposito R, Opravil M, and Hoy JF. (1996):** Rifabutin versus placebo in combination with three drugs in the treatment of nontuberculous mycobacterial infection in patients with AIDS. *Clin Infect Dis* 1996; 22:705-708.
- Dholakia R, and Almeida J. (1997):** The potential economic benefits of the DOTS strategy against TB in India. Geneva, World Health Organization, 1997 (document WHO/TB/96.218).
- Diamond G, and Bevins CL. (1998):** beta-Defensins: endogenous antibiotics of the innate host defense response. *Clin Immunol Immunopathol* 1998; 88: 221-5.
- Dickinson JM, and Mitchison DA. (1981):** Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. *Am Rev Respir Dis* 1981; 123:367--371.
- Dominguez-Castellano A., Muniain M.A. and Rodriguez-Bano J. (2003):** Factors associated with time to sputum smear

conversion in active pulmonary tuberculosis. *Int. J. Tuberc. Lung Dis.* 7:432-438.

Dorronsoro I, Martin C, Cabodevilla B, Ojer M, and Ruz A. (2000): [Effect of the number of samples studied on the diagnosis of tuberculosis] *Enferm Infecc Microbiol Clin* 2000; 18: 215-8.

Døssing M, Wilcke JTR, Askgaard DS, and Nybo B. (1996): Liver injury during antituberculosis treatment: an 11-year study. *Tuber Lung Dis* 1996; 77:335-340.

Doster B, Murray FJ, Newman R, and Woolpert SF. (1973): Ethambutol in the initial treatment of pulmonary tuberculosis. *Am Rev Respir Dis* 1973; 107:177-190.

Doster B., Murray F.J., Newman R. and Woolpert S.F. (2003): Treatment of tuberculosis. *Am. Fam. Physician*, Nov 1; 68 (9): 1854, 1857-8, 18612.

Drlicak and Malik M. (2003): Fluroquiolones: action and resistance. *Curr. Top. Med. chem.* 3:249-82.

Drucker D, Eggo MC, Salit IE, and Burrow GN. (1984): Ethionamide-induced goitrous hypothyroidism. *Ann Intern Med* 1984; 100:837-839.

DuMelle FJ, and Hopewell PC. (2000): The CDC and the American Lung Association/American Thoracic Society: an enduring public/private partnership. In: *Centers for Disease Control and Prevention: a century of notable events in TB control.* *TB Notes Newslett* 2000; 1:23-27.

Dye C, Watt CJ, Bleed DM, Mehran Hosseini S, and Raviglione MC. (2005): Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. *JAMA* 2005; 293: 2767-2775.

- Dye C. (1999):** Consensus statement: global burden of tuberculosis: estimated incidence, prevalence, and mortality by country: WHO Global Surveillance and Monitoring Project. JAMA 1999; 282:677-86.
- Dye C. (2006):** Global epidemiology of tuberculosis. Lancet 2006; 367: 938-40.
- Edward D. Chan Michael D. and Iseman. (2002):** Current medical treatment for tuberculosis, BMJ; 325: 1282-1286.
- Edward. D. (1960):** Story of tuberculin test. Quantitative aspect of tuberculin sensitivity. Am Rev. of Resp. Dis. Chapter 7 page. 28.
- Enarson DA, Rieder HL, Arnadotter T, and Trebucq A. (2000):** Management of TB - A Guide for Low-income countries, Paris: International union against tuberculosis and lung diseases, 2000; 63.
- Enator D, Bhattacharya M, Bozeman L, Burman W, Catanzaro A, and Chaisson R. (2002):** Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. Lancet 2002; 360:528-534.
- Essmat A. (1999):** Guide for national tuberculosis control program. Arab Republic of Egypt Ministry of health and population director general for health disease.
- Farer, L. S., L. M. Lowell, and M. P. Meador. (1979):** Extrapulmonary tuberculosis in the United States. Am. J. Epidemiol. 1979.
- Ferebee SH. (1970):** Controlled chemoprophylaxis trials in tuberculosis: A general review. Bibl Tuberc. 1970; 26:28-106.
- Ferrick DA, Schrenzel MD, Mulvania T, Hsieh B, Ferlin WG, and**

- Lepper H. (1995):** Differential production of interferon-gamma and interleukin-4 in response to Th1- and Th2-stimulating pathogens by gamma delta T cells in vivo. *Nature* 1995; 373: 255-7.
- Fodor T, Pataki G, and Schrettner M. (2000):** PAS infusion in treatment of multidrug-resistant tuberculosis [letter]. *Int J Tuberc Lung Dis* 2000;4:187--188.
- Forget E.J. and Menzies D. (2006):** Adverse reactions to first-line anti tuberculosis drugs. *Experopin Drug Saf.* S: 231-49.
- Frieden TR, Sherman LF, Maw KL, Fujiwara PI, Crawford JT, and Nivin B, et al. (1996):** A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. *JAMA* 1996;276:1229--1235.
- Fryatt RJ. (1997):** Review of published cost effectiveness studies on tuberculosis treatment programmes. *International Journal of Tuberculosis and Lung Disease*, 1997, 1:101--109.
- Gansert JL, Kiessler V, and Engele M.. (2003):** Human NKT cells express granulysin and exhibit antimycobacterial activity. *J Immunol* 2003; 170: 3154-61.
- Garcia-Romo GS, Pedroza-Gonzalez A, and Aguilar-Leon D. (2004):** Airways infection with virulent *Mycobacterium tuberculosis* delays the influx of dendritic cells and the expression of costimulatory molecules in mediastinal lymph nodes. *Immunology* 2004; 112: 661-8.
- Geiter LJ, and editor. (2000):** Ending neglect the elimination of tuberculosis in the United States. Institute of Medicine, Committee on Elimination of Tuberculosis in the United States. Washington, DC: National Academy Press; 2000.
- Gillespie SH, and Kennedy N. (1998):** Fluoroquinolones: a new treatment for tuberculosis? *Int J Tuberc Lung Dis* 1998;2:265--271.

- Giovanni F, Monica L, Marisa M, Barbara M, Roberto P, Pietro R, Barbara M, Roberto D, Patrizia, Fabio R, Leonardo M. and Luca R. (2005):** Routine Hospital Use of a New Commercial Whole Blood Interferon- γ Assay for the Diagnosis of Tuberculosis Infection. *American Journal of Respiratory and Critical Care Medicine* Vol 172. pp. 631-635, (2005).
- Girling DJ. (1977):** Adverse reactions to rifampicin in antituberculous regimens. *J Antimicrob Chemother* 1977;3:115-132.
- Girling DJ. (1982):** Adverse effects of antituberculous drugs. *Drugs* 1982;23:56-74.
- Girling DJ. (1984):** The role of pyrazinamide in primary chemotherapy for pulmonary tuberculosis. *Tubercle* 1984;65:1-4.
- Global tuberculosis control. (2009):** epidemiology, strategy, financing : WHO report 2009.
- Global tuberculosis control: surveillance, planning, financing. WHO Report. (2005):** / 2005.49. Geneva (Switzerland) 7 World Health Organization; 2005.
- Glynn JR, Jenkins PA, and Fine PE. (1995):** Patterns of initial and acquired antituberculosis drug resistance in Karonga District, Malawi. *Lancet* 1995; 345(8954): 907–10.
- Gonzalez E, Armas L, and Alonso A. (1994):** Tuberculosis in the Republic of Cuba: its possible elimination. *Tuber Lung Dis* 1994;75(3):188– 94.
- Gooding PG, Berman E, Lane AZ, and Agre K. (1976):** A review of results of clinical trials with amikacin. *J Infect Dis* 1976;134:S441-S445.
- Govt. of India. Ministry of Health and Family Welfare, Central TB Division: TB India. (2001):** RNTCP Status Report, New

Delhi; Govt. of India, 2001; 6-21.

Grassi C, and Peona V. (1996): Use of rifabutin in the treatment of pulmonary tuberculosis. Clin Infect Dis 1996;22:S50-S54.

Griffith DE, Brown BA, and Wallace RJ. (1996): Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus-negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease. Clin Infect Dis 1996;23:1321-1322.

Griffith DE, Brown BA, Girard WM, and Wallace RJ Jr. (1995): Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995;21:594-598.

Groups at risk: WHO report on the tuberculosis epidemic. (1996): WHO/TB/96.198. Geneva (Switzerland)7 World Health Organization; 1996.

Grzybowski,S., H. Fishault, J. Rowe, and A. Brown. (1971): Tuberculosis among patients with various radiologic abnormalities followed by the chest clinic service. Am. Rev. Respir. Dis. 104:605~08.

Guide for national tubeculosis control programe. (1999): Arab Republic of Egypt, Ministry of health and population director general for chest diseases.

Guidelines for establishing DOTS-PLUS pilot projects for the management of multidrug-resistant tuberculosis (MDRTB). (2000): WHO/CDS/TB/2000.279. Geneva (Switzerland)7 World Health Organization; 2000.

Guidelines for the programmatic management of drug-resistant tuberculosis. (2006): (WHO / HTM / 2006.361).

- Hafner R, Cohn JA, Wright DJ, Dunlap NE, Egorin MJ, Enama ME, Muth K, Peloquin CA, Mor N, and Heifets LB. (1997):** Early bactericidal activity of isoniazid in pulmonary tuberculosis. *Am J Respir Crit Care Med* 1997;156:918--923.
- Hernandez-Pando R, Jeyanathan M, and Mengistu G, et al. (2000):** Persistence of DNA from *Mycobacterium tuberculosis* in superficially normal lung tissue during latent infection. *Lancet* 2000; 356: 2133-8.
- Hesling CM. (1969):** Treatment with capreomycin, with special reference to toxic effects. *Tubercle* 1969;50:39-41.
- Hindi M. R. (2009):** Assessment of Directly Observed Therapy Short course (DOTS) of Tuberculosis in Benha Chest Hospital. Master Degree. Benha University.
- Hines N, Payeur JB, and Hoffman LJ. (2006):** Comparison of the recovery of *Mycobacterium bovis* isolates using the BACTEC MGIT 960 system, BACTEC 460 system, and Middlebrook 7H10 and 7H11 solid media. *J Vet Diagn Invest* 2006; 18: 243-50.
- Hopewell P. C. (1994):** Overview of clinical tuberculosis, p. 25-46. In: Bloom (2nd ed.), *Tuberculosis: pathogenesis, protection, and control*. American Society for Microbiology, Washington, D.C.
- Horsburgh CR Jr, Feldman S, and Ridzon R. (2000):** Practice guidelines for the treatment of tuberculosis. *Clin Infect Dis* 2000;31:633--639.
- Horsburgh, CR Jr. (2004):** Priorities for the treatment of latent tuberculosis infection in the United States. *N Engl J Med* 2004; 350:2060.

- Hsu KHK. (1984):** Thirty years after isoniazid: its impact on tuberculosis in children and adolescents. *JAMA* 1984;251:1283--1285.
- Human resources development for TB control. (2004):** report of a consultation held on 27 and 28 August 2003. World Health Organization/Rockefeller Foundation, Geneva, 2004 (2004.340).
- Iseman M.D. (2002):** Tuberculosis therapy: past, present and future. *Eur. Respir. J.* 20: 875-945.
- Jamison D. (1993):** Disease control priorities in developing countries: an overview. In: Jamison D et al. Disease control priorities in developing countries. New York, Oxford University Press, 1993.
- Jenner PJ, Ellard GA, Allan WG, Singh D, Girling DJ, and Nunn AJ. (1981):** Serum uric acid concentrations and arthralgia among patients treated with pyrazinamide-containing regimens in Hong Kong and Singapore. *Tubercle* 1981;62:175-179.
- Jones GS, Amirault HJ, and Andersen BR. (1990):** Killing of *Mycobacterium tuberculosis* by neutrophils: a nonoxidative process. *J Infect Dis* 1990; 162: 700-4.
- Junqueira-Kipnis AP, Kipnis A, and Jamieson A. (2003):** NK cells respond to pulmonary infection with *Mycobacterium tuberculosis*, but play a minimal role in protection. *J Immunol* 2003; 171: 6039-45.
- Keating LA, Wheeler PR, and Mansoor H. (2005):** The pyruvate requirement of some members of the *Mycobacterium tuberculosis* complex is due to an inactive pyruvate kinase: implications for in vivo growth. *Mol Microbiol* 2005; 56: 163-74.
- Kent PT, and Kubica GP. (1985):** Public Health Mycobacteriology: A

Guide for the Level III Laboratory. US Department of Health and Human Services, 1985. CDC, Atlanta, Georgia.

Kiblawi, S. O., S. J. Jay, R. B. Stonehill, and J. Norton. (1981): Fever response of patients on therapy for pulmonary tuberculosis. *Am. Rev. Respir. Dis.* 123:20-24.

Kilicaslan Z., Durmusoglu G., Tekdos D. and Ates S. (2002): Conversion rates of smear and culture in pulmonary tuberculosis by self treatment and effective factors. *Int. J. Tuberc. Lung Dis.* 6 (suppl1): S119.

Knapp RG, and miller MC. (1992): Clinical epidemiology and biostatistics (National Medical Series for Independent Study). Harwol Pub Co. 1-435.

Koumbaniou C, Nicopoulos C, Vassiliou M, Manda-Stachouli C, Sakellariou K, Demou GS, and Constantopoulos SH. (1998): Is pyrazinamide really the third drug of choice in the treatment of tuberculosis. *Int J Tuberc Lung Dis* 1998;2:675-678.

Kramer, F. T., A. R. Modelewsky, A. R. Walinay, J. M. Leedom, and P. F. Barnes. (1990): Delayed diagnosis of tuberculosis in patients with human immunodeficiency virus infection. *Am. J. Med.* 89:451-456.

Kremer L, and Besra.G. (2005): A waxy tale, by *Mycobacterium tuberculosis* p 287-305. In *Tuberculosis and the Tubercle bacillus*. ASM Press, Washington DC 2005.

Kucers A, and Bennett NM. (1988): The use of antibiotics: a comprehensive review with clinical emphasis, 4th edition. Philadelphia: Lippincott;1988:585-1436.

Leão SC, Martin A, Mejia GI, Palomino JC, Robledo J, and Telles MAS, Portaels F. (2004): Practical handbook for the phenotypic and genotypic identification of mycobacteria. Brugges, Vanden BROELLE, 2004, 164.

- Lee C-H, and Lee C-J. (1989):** Thrombocytopenia: a rare but potentially serious side effect of initial daily and interrupted use of rifampicin. *Chest* 1989;96:202-203.
- Leibold JE. (1966):** The ocular toxicity of ethambutol and its relation to dose. *Ann N Y Acad Sci* 1966;135:904-909.
- Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, and Stover CK. (1996):** Molecular analysis of genetic differences between *Mycobacterium bovis* BCG and virulent *M. bovis*. *J Bacteriol* 1996; 178: 1274-82.
- Mahapatra S, Basu J, Brennan P, and Crick D. (2005):** Structure, biosynthesis, and genetics of the Mycolic Acid-Arabinogalactan-Peptidoglycan complex. p 275-285. In *Tuberculosis and the Tubercle bacillus*. ASM Press, Washington DC.
- Management of tuberculosis. (2003):** Training for health facility staff- Module C – treat TB patients- World health organization – Geneva – 2003).
- Managing Pharmaceuticals and Commodities. (2005):** A Guide for National Tuberculosis Programs (Rational Pharmaceutical Management Plus, December 2005).
- Marinker M. and Shwaw J. (2003):** Not to be taken as directed. Putting concordance for taking medicines into practice. *BMJ*, 326: 348-9.
- Master, R.N. (1992):** Section Editor. "Mycobacteriology". *Clinical Microbiology Procedures Handbook*, Vol. 1, ASM, 1992, Washington, D.C.
- Mazurek GH, LoBue PA, and Daley CL. (2001):** Comparison of a whole-blood interferon- γ assay with tuberculin skin testing for detecting latent *Mycobacterium tuberculosis* infections. *JAMA* 2001;286:1740-1747.

- McDermott W, Ormond L, Muschenhein C, Deuschle K, McCune RM, and Tompsett R. (1954):** Pyrazinamide-isoniazid in tuberculosis. *Am Rev Tuberc* 1954;69:319-333.
- Mehta YS, Jijina FF, Badakere SS, Pathare AV, and Mohanty D. (1996):** Rifampin-induced immune thrombocytopenia. *Tuberc Lung Dis* 1996;77:558--562.
- Menzies R, and Vissandjee B. (1992):** Effect of bacille Calmette-Guerin vaccination on tuberculin reactivity. *Am Rev Respir Dis* 1992;145:621-625.
- Menzies RI. (2000):** Tuberculin skin testing. In: Reichman LB, Hershfield ES, eds. *Tuberculosis: a comprehensive international approach*. 2nd ed. New York: Marcel Dekker, 2000:279-322.
- Michael D. Iseman, and Goldman. (2007):** Cecil Medicine, Textbook of medicine, chapter 345, 23rd ed. 2007.
- Michael R. and Jacobs. (2004):** Fluroquinolones as chemotherapeutics against mycobacterial infections. *Current Pharmaceutical Design*, volume 10, No. 26.
- Ministry of Health and Population/ National Tuberculosis Control Programme. (2007):** Management of Tuberculosis Training for Chest Facility Staff / 2007 p.5-6.
- Ministry of Health and Population/ National Tuberculosis Control Programme. (2008):** TB Drug Management Guidelines, 2008.
- Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR, and Nelson SD. (1976):** Isoniazid liver injury: clinical spectrum, pathology and probably pathogenesis. *Ann Intern Med* 1976;84:81-192.
- Mitchison DA, and Nunn AJ. (1986):** Influence of initial drug resistance on the response to short-course chemotherapy of

pulmonary tuberculosis. Am Rev Respir Dis 1986;133:423--430.

Mitchison DA. (1985): Mechanisms of the action of drugs in short-course chemotherapy. Bull Int Union Tuberc 1985;60:36--40.

Miyakawa Y, Ratnakar P, and Rao AG. (1996): In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosis. Infect Immun 1996; 64: 926-32.

Mohamed S. AL- Hajjaj. (2000): The outcome of tuberculosis treatment after implementation of the National Tuberculosis Control Program in Saudi Arabia. Ann Saudi Med. 20 (2): 125-128.

Mohammad Tahir, Sarma S.K.,Duncan. Smith Rohrberg Deepak and Gupta. (2006): DOTS at a tertiary care centre in a northern India: success, challenges and the next steps in tuberculosis control. Indian J. Med. Res. 123, pp 702-706.

Mohan A., Nassir H. and Niazi A. (2003): Does routine home visiting improve the return rate and outcome of DOTS patients who delay treatment? East Mediterranean health journal, 9 (4): 702-8.

Morris JT, and Cooper RH. (1994): Intravenous streptomycin: a useful route of administration. Clin Infect Dis 1994;19:1150--1151.

Morse D, Brothwell DR, and Ucko PJ. (1964): Tuberculosis in ancient Egypt. Am Rev Respir Dis 1964; 90:524-541.

Morsy A.M., Zaher H.H, Hassan M.H. and Shouman. A. (2003): Predictors of treatment failure among tuberculosis patients under DOTS strategy in Egypt. Eastern Mediterranean Health Journal, volume. 9, No. 4.

- Mostowy S, Inwald J, and Gordon S. (2005):** Revisiting the evolution of *Mycobacterium bovis*. *J Bacteriol* 2005; 187: 6386-95.
- Moulding T, Dutt AK, and Reichman LB. (1995):** Fixed-dose combinations of antituberculous medications to prevent drug resistance. *Ann Intern Med* 1995;122:951--954.
- Mukherjee JS, Rich ML, and Socci AR. (2004):** Programmes and principles in treatment of multidrug-resistant tuberculosis. *Lancet* 2004;363(9407):474–81.
- Munt,P. W. (1971):** Miliary tuberculosis in the chemotherapy era with a clinical review in 69 American adults, *Medicine* 51:139-155.
- Murray CJ, DeJonghe E, and Chum HJ. (1991):** Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. *Lancet* 1991; 338(8778):1305–8.
- Murray FJ. (1956):** A pilot study of cycloserine toxicity: a United States Public Health Service cooperative clinical investigation. *Am Rev Respir Dis* 1956;74:196-209.
- Murray, H., C. Tuazon, N. Kirmani, and J. Sheagren. (1978):** The adult respiratory distress syndrome associated with military tuberculosis. *Chest* 73~3743.
- Narang RK. (1972):** Acute psychotic reaction probably caused by ethionamide. *Tubercle* 1972;53:137-138.
- Nash DR, and Douglass JE. (1980):** Anergy in active pulmonary tuberculosis: a comparison between positive and negative reactors and an evaluation of 5 TU and 250 TU skin test doses. *Chest* 1980;77:32-37.
- Nathanson E, Gupta R, and Huamani P. (2004):** Adverse events in the treatment of multidrug-resistant tuberculosis: results

from the DOTS plus initiative. *Int J Tuberc Lung Dis* 2004;8(11):1382–4.

National Tuberculosis Control Program. (1996): Ministry of Health and Population.

National Tuberculosis Control Program. (1998): Ministry of Health and Population.

National Tuberculosis Control Program. (1999): Ministry of Health and Population.

National Tuberculosis Control Program. (2002): Ministry of Health and Population.

National Tuberculosis Control Program. (2006): Ministry of Health and Population.

National Tuberculosis Control Program. (2008): Ministry of Health and Population.

Niemann S, Richter E and Rusch-Gerdes S. (2002): Biochemical and genetic evidence for the transfer of *Mycobacterium tuberculosis* subsp. *Caprae* Aranaz et al. 1999 to the species *Mycobacterium bovis* Karlson and Lessel 1970 (Approved Lists 1980) as *Mycobacterium bovis* subsp. *caprae* comb. nov. *Int J Syst Evol Microbiol* 2002; 52: 433-6.

Niemann S, Richter E, and Rusch-Gerdes S. (2000): Differentiation among members of the *Mycobacterium tuberculosis* complex by molecular and biochemical features: evidence for two pyrazinamide-susceptible subtypes of *M. bovis*. *J Clin Microbiol* 2000; 1: 152-7.

Nuermberger E. and Grosset J. (2004): Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. *Eur. J. Clin. Microbiol. Infect. Dis.* 23: 243-55.

- Oof F. M. (1976):** The notification of pulmonary tuberculosis in Khalifa region. Thesis for Master degree (chest), Ain-Shams University.
- Palomino , Leão , and Ritacco. (2007):** Tuberculosis From basic science to patient care / First Edition.
- Peloquin CA, Berning SE, Huitt GW, Childs JM, Singleton MD, and James GT. (1999):** Once-daily and twice-daily dosing of *p*-aminosalicylic acid granules. *Am J Respir Crit Care Med* 1999;159:932-934.
- Peloquin CA, Henshaw TL, Huitt GW, Berning SE, Nitta AT, and James GT. (1994):** Pharmacokinetic evaluation of para-aminosalicylic acid granules. *Pharmacotherapy* 1994;14:40-46.
- Peloquin CA, Vernon A, Burman W, and Benator D. (1999):** Pharmacokinetics of rifapentine, rifampin, and isoniazid in TB patients [abstract]. *Am J Respir Crit Care Med* 1999;159:A16.
- Peloquin CA. (1997):** Using therapeutic drug monitoring to dose the antimycobacterial drugs. *Clin Chest Med* 1997;18:79-87.
- Pernod J. (1965):** Hepatic tolerance of ethionamide. *Am Rev Respir Dis* 1965;92:39-42.
- Perriens JH, St Louis ME, and Mukadi YB. (1995):** Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. *N Engl J Med* 1995;332(12):779– 84.
- Pinet G. (2001):** Good practice in legislation and regulations for TB control: an indicator of political will. Geneva, World Health Organization, 2001 WHO/CDS/TB/2001.290.

- Poole G, Stradling P, and Worlledge S. (1971):** Potentially serious side effects of high-dose twice-weekly rifampicin. *BMJ* 1971;3:343-347.
- Prout,S., and S. R. Benatar. (1980):** Disseminated tuberculosis: a study of 62 cases. *S. Afr. Med. J.* 58:835-842.
- Rashwan A. A. (1993):** Statistical data analysis for tuberculous patients followed up in the chest clinic in Abo. EL. Rish. Hospital. Master Degree. Cairo University.
- Ratnan S and Chandrasekhar S. (1976):** The pathogenicity of spheroplasts of *Mycobacterium tuberculosis*. *Amer Rev Respir Dis* 1976; 114: 549-54.
- Raviglione MC, and Smith IM. (2007):** XDR tuberculosis. implications for global public health. *N Engl J Med* 2007; 356: 656-9.
- Reuter H, Burgess L, van Vuuren W, and Doubell A. (2006):** Diagnosing tuberculous pericarditis. *QJM* 2006; 99: 827-39.
- Rieder HL. (1996):** Sputum smear conversion during directly observed treatment for tuberculosis. *Tuber Lung Dis.* 1996 Apr; 77(2):124-9.
- Robert M. Jasmer, Christopher B, Seaman, Lead C, Gonzalez and Kawamura et al., (2004):** Directly observed therapy compared with self administered therapy. *American Journal of Respiratory and Critical Care Medicine.* Vol.170. pp. 561-566.
- Robert M. Jasmer, M.D., Payam Nahid, M.D., and Philip C. and Hopewell, M.D. (2002):** Latent Tuberculosis Infection. *The New England Journal of Medicine*, December 5, 2002, Number 23. Volume 347:1860-1866.

- Rothfield TG, Bierer WF, and Garfield JW. (1978):** Isoniazid induction of antinuclear antibodies. *Ann Intern Med* 1978;88:650-652.
- Roya Alavia-Naini, Bastool Sharifi-Mood and Malihe Metanat (2007):** The gender difference in tuberculosis in a highly endemic region of Iran. *J. Med. Sci.* 7(7):1218-1220.
- Sahn, S., and T. Neff. (1974):** Miliary tuberculosis. *Am. J. Med.* 56:495,505.
- Sander CC. (1991):** Review of preclinical studies with ofloxacin. *Clin Infect Dis* 1991;14:526--538.
- Sanders WEJ. (1976):** Rifampin. *Ann Intern Med* 1976;85:82-86.
- Sarah R Anderson, Helen Maguire, and Jacqui Carless. (2007):** Tuberculosis in London: a decade and a half of no decline. *058313Thorax* 2007;62:162-167.
- Saunderson PR. (1995):** An economic evaluation of alternative programme designs for tuberculosis control in rural Uganda. *Social Science and Medicine*, 1995, 40:1203–1212.
- Sawert H, Kongsin S, and Payanandana V. (1997):** Costs and benefits of improving tuberculosis control: the case of Thailand. *Soc Sci Med* 1997;44(12):1805– 16.
- Serbina NV, Lazarevic V, and Flynn JL. (2001):** CD4(+) T cells are required for the development of cytotoxic CD8(+) T cells during *Mycobacterium tuberculosis* infection. *J Immunol* 2001; 167: 6991-7000.
- Shafran SD, Deschenes J, Miller M, Phillips P, and Toma E. (1994):** Uveitis and pseudo-jaundice during a regimen of clarithromycin, rifabutin and ethambutol. *N Engl J Med* 1994;330:438-439.

- Shafran SD, Singer J, Zarowny DP, Phillips P, Salit I, and Walmsley SL. (1996):** A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazamine, and ciprofloxacin. *N Engl J Med* 1996;335:377-383.
- Sherif S. E. (2004):** A study of the annual infection rate of tuberculosis in Sohag City, Master Degree. Cairo University.
- Singh A.A, Arora R, Ware D.F, Chauhan L.S, and Granich R. (2005):** Involvement of Non allopathic private practitioners under DOTS in an urban area of North India, *Indian J. Tuberc.* 52: 184-187.
- Singla R, Singla N, Sarin R, and Arora VK.L.R. (2005):** Influence of pre-treatment bacillary load on treatment outcome of pulmonary tuberculosis patients receiving DOTS under revised national tuberculosis control programme. *Indian J Chest Dis Allied Sci.* 2005 Jan-Mar; 47(1):19-23.
- Slavin,R. E., T. J. Walsh, and A. D. Pollack. (1980):** Late generalized tuberculosis: a clinical pathologic analysis of 100 cases in the pre antibiotic and antibiotic eras. *Medicine* 59:352-366.
- Slutkin G, Perez-Stable EJ, and Hopewell PC. (1986):** Time course and boosting of tuberculin reactions in nursing home residents. *Am Rev Respir Dis* 1986;134:1048-1051.
- Small, P. M., G. F. Schechter, P. C. Goodman, M. A. Sande, R. E. Chaisson, and P. C. Hopewell. (1991):** Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. *N.Engl.J. Med.* 1991; 324:289-294.
- Smith I. (2004):** What is the health, social, and economic burden of tuberculosis. 2004 p. 233-7, In: nd.

- Snider DE. (1980):** Pyridoxine supplementation during isoniazid therapy. *Tubercle* 1980;61:191-196.
- Sola C, Rastogi N, Gutierrez MC, Vincent V, Brosch R. and Parsons L. (2003):** Is *Mycobacterium africanum* subtype II (Uganda I and Uganda II) a genetically well-defined subspecies of the *Mycobacterium tuberculosis* complex? *J Clin Microbiol* 2003; 41: 1345-6.
- Stead, W. W., G.R. Kerby, D. P. Schlueter, and C. W. Jordahl. (1968):** The clinical spectrum of primary tuberculosis in adults: confusion with reinfection in the pathogenesis of chronic tuberculosis. *Ann. Zntern. Med.* 68:731-745.
- Steele MA, Burk RF, and DesPrez RM. (1991):** Toxic hepatitis with isoniazid and rifampin: a meta-analysis. *Chest* 1991;99:465--471.
- Stenger S, Mazzaccaro RJ, and Uyemura K. (1997):** Differential effects of cytolytic T cell subsets on intracellular infection. *Science* 1997; 276: 1684-7.
- Sterling TR, Lehmann HP, and Frieden TR. (2003):** Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. *BMJ* 2003;326(7389):574– 9.
- Stop Tuberculosis Initiative. (1999):** Report by the Director-General. Geneva, World Health Organization, 1999 (document EB105/13).
- Styblo K. (1991):** Epidemiology of tuberculosis. Selected papers, vol. 24, KNCV, 1991.
- Sun E, Heath-Chiozzi M, Cameron DW, Hsu A, Granneman RG, Maurath CJ, and Leonard JM. (1996):** Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse events [abstract Mo.B.171]. In: XI International

Conference on AIDS, Vancouver, Canada, July 7--12, 1996;11:18.

Swash M, Roberts AH, and Murnaghan DJ. (1972): Reversible pellagra-like encephalopathy with ethionamide and cycloserine. *Tubercle* 1972;53:132-136.

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. (2000): ATS Official Statement. *Am. J. Respir. Crit. Care Med.* 2000; 161: 1376- 95.

Tarnoky AL, and Steingold L. (1951): The action of *p*-aminosalicylic acid on prothrombin time in man. *J Clin Pathol* 1951;4:478--486.

Task Analysis. (2005): The basis for development of training in management of tuberculosis. Geneva, World Health Organization (WHO/HTM/TB/2005.354).

TB deaths reach historic levels. (1996): [press release WHO/22, 1996]. Geneva (Switzerland) 7 World Health Organization; March 21, 1996.

The 2000 ATS/CDC guidelines also advocated a 2- or 3-month regimen of RIF/PZA. (2000): However, due to a considerable risk of serious, even lethal hepatitis, this regimen does not seem to be an acceptable alternative.

The Stop TB Strategy STRATEGY. (2006): Building on and enhancing DOTS to meet the TB-related Millennium Development Goals World Health Organization 2006 WHO/HTM/TB/2006.368.

The world health report (2004): changing history. Geneva (Switzerland) 7 World Health Organization; 2004.

Thomas R. Frieden, MPH, Sonal S. and Munsiff. (2005): The DOTS Strategy for Controlling the Global Tuberculosis Epidemic. New York City Department of Health and

Mental Hygiene, 125 Worth Street, New York, NY 10013, USA, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA, USA Clin Chest Med 26 (2005) 197 – 205.

Tolba F., Abdel Maseh O., Mokhtar A. and Decoster, E. (1995): Defaulting in Damietta Governorate, NTP, 1995.

Toman's Tuberculosis. (2004): Case detection, treatment, and monitoring – questions and answers, SECOND EDITION, Edited by T. Frieden WORLD HEALTH ORGANIZATION, GENEVA, 2004.

Toutoungi M, Carroll RLA, Enrico J-F, and Perey L. (1985): Cheese, wine, and isoniazid. Lancet 1985; ii: 671.

Treatment of tuberculosis: guidelines for national programmes. (2003): 3rd edition.WHO/CDS/TB/2003.313. Geneva (Switzerland) 7 World Health Organization; 2003.

Trebucq A. (1997): Should ethambutol be recommended for routine treatment of tuberculosis in children? A review of the literature. Int J Tuberc Lung Dis 1997; 1:12-15.

Tuberculosis Chemotherapy Centre. (1964): Madras. A concurrent comparison of intermittent (twice weekly) isoniazid plus streptomycin and daily isoniazid plus PAS in the domiciliary treatment of pulmonary tuberculosis. Bull World Health Organ 1964;31:247.

Tugwell P, and James SL. (1972): Peripheral neuropathy with ethambutol. Postgrad Med J 1972; 48:667-670.

United States Pharmacopeial Dispensing Information. (1999): Drug Information for the Health Care Professional. Vol. I. Englewood, CO: Micromedex, 1999:69--1419.

Urban CF, Lourido S, and Zychlinsky A. (2006): How do microbes evade neutrophil killing? Cell Microbiol 2006; 8: 1687-96.

- Wayne LG. (1982):** Microbiology of tubercle bacilli. Am Rev Respir Dis 1982; 125: 31-41.
- Weinstein HJ, Hallett WY, and Sarauw AS. (1962):** The absorption and toxicity of ethionamide. Am Rev Respir Dis 1962;86:576-578.
- Weir, M. R., and G. R. and Thornton. (1985):** Extrapulmonary tuberculosis: experience of a community hospital and review of the literature. Am. J.Med. 79:467-478.
- WHO Library Cataloguing in Publication Data. (2007):** WHO. Global tuberculosis control, surveillance, planning, financing. Geneva: WHO, 2007. Report No WHO/HTM/TB/2007.376.
- WHO library cataloguing in publication Data. (2008):** Implementing the WHO Stop TB Strategy: a handbook for national tuberculosis control programmes. WHO/HTM/2008.401.
- WHO Library Cataloguing in Publication Data. (2009):** Global tuberculosis control : epidemiology, strategy, financing : WHO report 2009. WHO/HTM/TB/2009.411.
- WHO. (2003):** Tuberculosis Fact Sheet. No. 104. Geneva: WHO 2003; 1-3.
- WHO. Global tuberculosis control, surveillance, planning, financing. (2007):** Geneva: WHO, 2007. Report No WHO/HTM/TB/2007.376.
- WHO. Global tuberculosis control: a short update to the 2009 report. (2010):** Global tuberculosis control - epidemiology, strategy, financing > Global tuberculosis control: a short update to the 2009 report 2010.
- WHO. Global tuberculosis control: surveillance, planning, financing. (2005):** WHO Report 2005. WHO/TB/ 2005.49. Geneva (Switzerland)7 World Health Organization; 2005.

- WHO. *Guidelines for the programmatic management of drug-resistant tuberculosis. (2006):*** Geneva, World Health Organization, 2006 (WHO/HTM/TB/2006.361).
- WHO. *Task Analysis. (2005):*** The basis for development of training in management of tuberculosis. Geneva, World Health Organization (WHO/TB/2005.354).
- WHO. *The Stop TB Strategy. (2006):*** Building on and enhancing DOTS to meet the TB-related Millennium Development Goals World Health Organization 2006. WHO/TB/2006.368.
- Wilkinson RJ, Haslov K, and Rappuoli R. (1997):** Evaluation of the recombinant 38-kilodalton antigen of Mycobacterium tuberculosis as a potential immunodiagnostic reagent. J Clin Microbiol 1997; 35: 553-7.
- World Bank. *Investing in Health. (1993):*** World Development Report. Oxford,Oxford University Press, 1993.
- World Health Organization. (1999):** What is DOTS? A guide to understanding the WHO-recommended TB control strategy known as DOTS. WHO/CDS/CPC/TB/99.270. Geneva, Switzerland: World Health Organization; 1999.
- World Health Organization. (2002a):** An expanded DOTS framework for effective tuberculosis control. Geneva, Switzerland: WHO, 2002. (WHO/CDS/TB/2002.297).
- World Health Organization. (2002b):** Strategic framework to decrease the burden of TB/HIV. Geneva, WHO, (WH/CDS/TB/2002.296).
- World Health Organization. (2005):** Administration Centre data. Cairo, WHO. Eastern Mediterranean Regional office.
- World Health Organization. (2006):** Global tuberculosis control: surveillance, planning and financing. Geneva, Switzerland:

WHO; 2006. Publication WHO/TB/2006.362.

World Health Organization. 4 million treatments in 4 years. (2005): Achievement report - special edition. Geneva, World Health Organization, 2005.

World Health Organization. An expanded DOTS framework for effective tuberculosis control. (2002): Geneva, World Health Organization, 2002 (WHO/CDS/TB/2002.297).

World Health Organization. Anti-tuberculosis drug resistance in the world. (2004): report no. 3, prevalence and trends. WHO/TB/2004. 343. Geneva (Switzerland) 7 World Health Organization.

World Health Organization. Global tuberculosis control: surveillance, planning, financing. (2005): WHO Report 2005. WHO/TB/ 2005.49. Geneva (Switzerland) 7 World Health Organization; 2005.

World Health Organization. Guidelines for establishing DOTS-PLUS pilot projects for the management of multidrug-resistant tuberculosis (MDRTB). (2000): WHO/CDS/TB/2000.279. Geneva (Switzerland) 7 World Health Organization; 2000.

World Health Organization. Joint tuberculosis programme review: India, February. (2000). New Delhi, World Health Organization Regional Office for South-East Asia, 2000 (document SEA-TB-224).

World Health Organization. Treatment of tuberculosis. (2003): guidelines for national programmes, 3rd ed. Geneva, World Health Organization (WHO/CDS/TB/2003.313).

World Health Organization. Washington Commitment to Stop TB. (2001): First Stop TB Partners' Forum, 22–23 October 2001. Geneva, World Health Organization, 2001.

- World Health Organization. *What is DOTS?. (1999):*** A guide to understanding the WHO-recommended TB control strategy known as DOTS. Geneva, World Health Organization, 1999 (document WHO/CDS/CPC/ TB/99.270).
- Yassin MA, and Cuevas LE. (2003):** How many sputum smears are necessary for case finding in pulmonary tuberculosis? *Trop Med Int Health* 2003; 8: 927-32.
- Yegian D, and Vanderlinde RJ. (1947):** The nature of acid-fastness. *J Bacteriol* 1947; 54: 777-83.
- Zaher H. (1996):** Tuberculosis situation in Egypt, the fifth international conference of microbiology, AIDS and emerging infectious diseases. Cairo, Egypt.174:935-52.
- Zhu M, Burman WJ, Jaresko GS, Berning SE, Jelliffe RW, and Peloquin CA. (2001):** Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. *Pharmacotherapy* 2001; 21:1037-1045.